帕金森病的临床基因检测应成为常规患者护理的一部分。
Clinical genetic testing in Parkinson's disease should become part of routine patient care.
机构信息
Department of Neurology and Neurosurgery, McGill University, Montreal, QC H3A 2B4, Canada.
Clinical Research Unit, The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC H3A 2B4, Canada.
出版信息
Brain. 2024 Aug 1;147(8):2595-2597. doi: 10.1093/brain/awae181.
Abstract
This scientific commentary refers to ‘Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s Disease Study’ by Westenberger (https://doi.org/10.1093/brain/awae188) and ‘Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study’ by Cook . (https://doi.org/10.1093/brain/awae142).
摘要
本科学评论提到了 Westenberger 的“基因靶向试验时代遗传检测的相关性：罗斯托克帕金森病研究”（https://doi.org/10.1093/brain/awae188）和 Cook 的“帕金森病变异检测和披露：北美的 PD GENEration 研究”（https://doi.org/10.1093/brain/awae142）。
相似文献
1
Clinical genetic testing in Parkinson's disease should become part of routine patient care.帕金森病的临床基因检测应成为常规患者护理的一部分。
Brain. 2024 Aug 1;147(8):2595-2597. doi: 10.1093/brain/awae181.
2
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.帕金森病变异检测与披露：北美研究项目“PD基因计划”
Brain. 2024 Aug 1;147(8):2668-2679. doi: 10.1093/brain/awae142.
3
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.基因靶向试验时代基因检测的相关性：罗斯托克帕金森病研究
Brain. 2024 Aug 1;147(8):2652-2667. doi: 10.1093/brain/awae188.
4
Navigating the open sea of commercial genetic testing in Parkinson's disease.在帕金森病商业基因检测的广阔领域中探索。
Parkinsonism Relat Disord. 2021 Nov;92:105-106. doi: 10.1016/j.parkreldis.2021.10.027. Epub 2021 Oct 29.
5
Genetic Testing in Parkinson's Disease.帕金森病的基因检测。
Mov Disord. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27.
6
Genetic testing for Parkinson's disease in Israel: Insights from the Rostock Parkinson's Disease (ROPAD) study.以色列帕金森病的基因检测：罗斯托克帕金森病（ROPAD）研究的见解
Parkinsonism Relat Disord. 2025 Aug;137:107940. doi: 10.1016/j.parkreldis.2025.107940. Epub 2025 Jun 28.
7
Genetic testing in Parkinson's disease.帕金森病的基因检测
Mov Disord. 2005 Jul;20(7):908-9. doi: 10.1002/mds.20509.
8
Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.帕金森病认知衰退的遗传风险因素：文献综述。
Eur J Neurol. 2017 Apr;24(4):561-e20. doi: 10.1111/ene.13258. Epub 2017 Feb 21.
9
Commentary on "A genome wide linkage disequilibrium screen in Parkinson's disease" by Foltynie et al. in J Neurol (2005) 252:597-602.对Foltynie等人发表于《神经病学杂志》（2005年）第252卷，第597 - 602页的“帕金森病全基因组连锁不平衡筛查”一文的评论
J Neurol. 2005 May;252(5):603-4. doi: 10.1007/s00415-005-0707-1. Epub 2005 Mar 7.
10
[Genetic testing for Parkinson's disease: indication and practical implementation].[帕金森病的基因检测：指征与实际应用]
Fortschr Neurol Psychiatr. 2020 Sep;88(9):601-608. doi: 10.1055/a-1155-6389. Epub 2020 Jun 28.
引用本文的文献
1
Barriers to clinical genetic testing in movement disorders.运动障碍临床基因检测的障碍
Curr Opin Neurol. 2025 Aug 1;38(4):355-360. doi: 10.1097/WCO.0000000000001381. Epub 2025 May 21.
2
Deep Brain Stimulation Improves Symptoms in an Individual with Alpha-Synuclein-Gene-Associated Parkinson's Disease.深部脑刺激改善α-突触核蛋白基因相关帕金森病患者的症状。
Mov Disord Clin Pract. 2025 Aug;12(8):1200-1203. doi: 10.1002/mdc3.70057. Epub 2025 Mar 29.
3
Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.GBA1基因变异的分类及基因型-表型关系：MDSGene系统评价
Mov Disord. 2025 Apr;40(4):605-618. doi: 10.1002/mds.30141. Epub 2025 Feb 10.
4
A Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases.计算方法在神经退行性疾病药物发现中的应用研究综述
Biomolecules. 2024 Oct 19;14(10):1330. doi: 10.3390/biom14101330.
本文引用的文献
1
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.基因靶向试验时代基因检测的相关性：罗斯托克帕金森病研究
Brain. 2024 Aug 1;147(8):2652-2667. doi: 10.1093/brain/awae188.
2
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.帕金森病变异检测与披露：北美研究项目“PD基因计划”
Brain. 2024 Aug 1;147(8):2668-2679. doi: 10.1093/brain/awae142.
3
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.常染色体显性遗传帕金森病中的 RAB32 Ser71Arg：连锁、关联和功能分析。
Lancet Neurol. 2024 Jun;23(6):603-614. doi: 10.1016/S1474-4422(24)00121-2. Epub 2024 Apr 10.
4
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.在非洲和非洲混合人群中与帕金森病相关的遗传风险基因座和因果关系的鉴定：一项全基因组关联研究。
Lancet Neurol. 2023 Nov;22(11):1015-1025. doi: 10.1016/S1474-4422(23)00283-1. Epub 2023 Aug 23.
5
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.Venglustat 治疗 GBA1 相关帕金森病的安全性和疗效：一项国际性、多中心、双盲、随机、安慰剂对照的 2 期临床试验。
Lancet Neurol. 2023 Aug;22(8):661-671. doi: 10.1016/S1474-4422(23)00205-3.
6
Clinical testing panels for ALS: global distribution, consistency, and challenges.肌萎缩侧索硬化症的临床检测面板：全球分布、一致性和挑战。
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):420-435. doi: 10.1080/21678421.2023.2173015. Epub 2023 Mar 10.
7
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.帕金森病与丘脑底核脑深部电刺激：GBA 基因突变携带者的认知影响。
Ann Neurol. 2022 Mar;91(3):424-435. doi: 10.1002/ana.26302. Epub 2022 Jan 25.
8
New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.针对 GBA、LRRK2 和 Parkin 的帕金森病新治疗方法。
Neuropharmacology. 2022 Jan 1;202:108822. doi: 10.1016/j.neuropharm.2021.108822. Epub 2021 Oct 7.
9
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.帕金森病的遗传学：对精准医学之旅的反思。
Neurobiol Dis. 2020 Apr;137:104782. doi: 10.1016/j.nbd.2020.104782. Epub 2020 Jan 25.
10
Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.GTP环化水解酶1突变携带者中的帕金森病
Brain. 2014 Sep;137(Pt 9):2480-92. doi: 10.1093/brain/awu179. Epub 2014 Jul 2.
Zotero 插件